|
Gene: ZNF770 |
Gene summary for ZNF770 |
Gene summary. |
Gene information | Species | Human | Gene symbol | ZNF770 | Gene ID | 54989 |
Gene name | zinc finger protein 770 | |
Gene Alias | PRO1914 | |
Cytomap | 15q14 | |
Gene Type | protein-coding | GO ID | GO:0006139 | UniProtAcc | Q6IQ21 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
54989 | ZNF770 | LZE2T | Human | Esophagus | ESCC | 3.45e-06 | 5.33e-01 | 0.082 |
54989 | ZNF770 | LZE4T | Human | Esophagus | ESCC | 1.35e-14 | 2.78e-01 | 0.0811 |
54989 | ZNF770 | LZE8T | Human | Esophagus | ESCC | 1.56e-04 | -2.94e-02 | 0.067 |
54989 | ZNF770 | LZE20T | Human | Esophagus | ESCC | 4.78e-02 | -4.30e-02 | 0.0662 |
54989 | ZNF770 | LZE24T | Human | Esophagus | ESCC | 7.30e-13 | 1.29e-01 | 0.0596 |
54989 | ZNF770 | LZE21T | Human | Esophagus | ESCC | 1.60e-02 | 1.15e-01 | 0.0655 |
54989 | ZNF770 | LZE6T | Human | Esophagus | ESCC | 1.18e-03 | -6.62e-03 | 0.0845 |
54989 | ZNF770 | P1T-E | Human | Esophagus | ESCC | 4.80e-03 | 2.20e-01 | 0.0875 |
54989 | ZNF770 | P2T-E | Human | Esophagus | ESCC | 6.86e-25 | 2.34e-01 | 0.1177 |
54989 | ZNF770 | P4T-E | Human | Esophagus | ESCC | 1.47e-17 | 6.23e-01 | 0.1323 |
54989 | ZNF770 | P5T-E | Human | Esophagus | ESCC | 6.29e-16 | 3.45e-01 | 0.1327 |
54989 | ZNF770 | P8T-E | Human | Esophagus | ESCC | 7.45e-21 | 3.25e-01 | 0.0889 |
54989 | ZNF770 | P9T-E | Human | Esophagus | ESCC | 2.31e-13 | 1.52e-01 | 0.1131 |
54989 | ZNF770 | P10T-E | Human | Esophagus | ESCC | 3.28e-29 | 6.04e-01 | 0.116 |
54989 | ZNF770 | P11T-E | Human | Esophagus | ESCC | 1.77e-07 | 2.40e-01 | 0.1426 |
54989 | ZNF770 | P12T-E | Human | Esophagus | ESCC | 3.32e-23 | 3.89e-01 | 0.1122 |
54989 | ZNF770 | P15T-E | Human | Esophagus | ESCC | 2.91e-23 | 3.95e-01 | 0.1149 |
54989 | ZNF770 | P16T-E | Human | Esophagus | ESCC | 2.40e-28 | 5.21e-01 | 0.1153 |
54989 | ZNF770 | P19T-E | Human | Esophagus | ESCC | 6.06e-06 | 1.52e-01 | 0.1662 |
54989 | ZNF770 | P20T-E | Human | Esophagus | ESCC | 1.44e-14 | 2.28e-01 | 0.1124 |
Page: 1 2 3 4 5 6 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Esophagus | ESCC | |
Skin | AK | |
Skin | SCCIS | |
Skin | cSCC | |
Thyroid | HT |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 2 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
ZNF770 | SNV | Missense_Mutation | novel | c.73A>T | p.Arg25Trp | p.R25W | Q6IQ21 | protein_coding | deleterious(0) | probably_damaging(0.962) | TCGA-A7-A6VW-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | CR |
ZNF770 | SNV | Missense_Mutation | novel | c.2023N>T | p.His675Tyr | p.H675Y | Q6IQ21 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-AC-A3W7-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | femara | SD |
ZNF770 | SNV | Missense_Mutation | rs140429599 | c.1618G>C | p.Gly540Arg | p.G540R | Q6IQ21 | protein_coding | tolerated(0.1) | benign(0.125) | TCGA-AN-A0FW-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
ZNF770 | SNV | Missense_Mutation | novel | c.322C>G | p.Gln108Glu | p.Q108E | Q6IQ21 | protein_coding | tolerated(0.24) | benign(0.084) | TCGA-AQ-A7U7-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Targeted Molecular therapy | rituximab | CR |
ZNF770 | SNV | Missense_Mutation | rs768441646 | c.1877N>A | p.Arg626Gln | p.R626Q | Q6IQ21 | protein_coding | tolerated(1) | benign(0) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
ZNF770 | SNV | Missense_Mutation | novel | c.470N>C | p.Lys157Thr | p.K157T | Q6IQ21 | protein_coding | deleterious(0.01) | possibly_damaging(0.835) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
ZNF770 | SNV | Missense_Mutation | novel | c.1610N>C | p.Val537Ala | p.V537A | Q6IQ21 | protein_coding | tolerated(0.12) | benign(0.003) | TCGA-ZJ-AAXA-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
ZNF770 | SNV | Missense_Mutation | c.1981N>G | p.Thr661Ala | p.T661A | Q6IQ21 | protein_coding | deleterious(0.01) | benign(0.056) | TCGA-A6-6141-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Chemotherapy | 5-fu | SD | |
ZNF770 | SNV | Missense_Mutation | c.1528N>G | p.Lys510Glu | p.K510E | Q6IQ21 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AA-3710-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
ZNF770 | SNV | Missense_Mutation | novel | c.1321N>C | p.Ser441Pro | p.S441P | Q6IQ21 | protein_coding | tolerated(0.15) | benign(0) | TCGA-AA-A00N-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
Page: 1 2 3 4 5 6 7 8 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |